335 related articles for article (PubMed ID: 24416201)
21. Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study.
Becker H; Marcucci G; Maharry K; Radmacher MD; Mrózek K; Margeson D; Whitman SP; Wu YZ; Schwind S; Paschka P; Powell BL; Carter TH; Kolitz JE; Wetzler M; Carroll AJ; Baer MR; Caligiuri MA; Larson RA; Bloomfield CD
J Clin Oncol; 2010 Feb; 28(4):596-604. PubMed ID: 20026798
[TBL] [Abstract][Full Text] [Related]
22. TET2 expression is a potential prognostic and predictive biomarker in cytogenetically normal acute myeloid leukemia.
Zhang TJ; Zhou JD; Yang DQ; Wang YX; Wen XM; Guo H; Yang L; Lian XY; Lin J; Qian J
J Cell Physiol; 2018 Aug; 233(8):5838-5846. PubMed ID: 29219176
[TBL] [Abstract][Full Text] [Related]
23. Allogeneic hematopoietic stem cell transplantation could improve survival of cytogenetically normal adult acute myeloid leukemia patients with DNMT3A mutations.
Xu Y; Sun Y; Shen H; Ding L; Yang Z; Qiu H; Sun A; Chen S; Wu D
Am J Hematol; 2015 Nov; 90(11):992-7. PubMed ID: 26223865
[TBL] [Abstract][Full Text] [Related]
24. PARP-1 Overexpression as an Independent Prognostic Factor in Adult Non-M3 Acute Myeloid Leukemia.
Pashaiefar H; Yaghmaie M; Tavakkoly-Bazzaz J; Ghaffari SH; Alimoghaddam K; Momeny M; Izadi P; Izadifard M; Kasaeian A; Ghavamzadeh A
Genet Test Mol Biomarkers; 2018 Jun; 22(6):343-349. PubMed ID: 29812960
[TBL] [Abstract][Full Text] [Related]
25. Long non-coding RNA HOXB-AS3 promotes myeloid cell proliferation and its higher expression is an adverse prognostic marker in patients with acute myeloid leukemia and myelodysplastic syndrome.
Huang HH; Chen FY; Chou WC; Hou HA; Ko BS; Lin CT; Tang JL; Li CC; Yao M; Tsay W; Hsu SC; Wu SJ; Chen CY; Huang SY; Tseng MH; Tien HF; Chen RH
BMC Cancer; 2019 Jun; 19(1):617. PubMed ID: 31234830
[TBL] [Abstract][Full Text] [Related]
26. Expression of Hedgehog Pathway Mediator GLI Represents a Negative Prognostic Marker in Human Acute Myeloid Leukemia and Its Inhibition Exerts Antileukemic Effects.
Wellbrock J; Latuske E; Köhler J; Wagner K; Stamm H; Vettorazzi E; Vohwinkel G; Klokow M; Uibeleisen R; Ehm P; Riecken K; Loges S; Thol F; Schubert C; Amling M; Jücker M; Bokemeyer C; Heuser M; Krauter J; Fiedler W
Clin Cancer Res; 2015 May; 21(10):2388-98. PubMed ID: 25745035
[TBL] [Abstract][Full Text] [Related]
27. Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia.
Thol F; Damm F; Lüdeking A; Winschel C; Wagner K; Morgan M; Yun H; Göhring G; Schlegelberger B; Hoelzer D; Lübbert M; Kanz L; Fiedler W; Kirchner H; Heil G; Krauter J; Ganser A; Heuser M
J Clin Oncol; 2011 Jul; 29(21):2889-96. PubMed ID: 21670448
[TBL] [Abstract][Full Text] [Related]
28. Downregulation of the Wnt inhibitor CXXC5 predicts a better prognosis in acute myeloid leukemia.
Kühnl A; Valk PJ; Sanders MA; Ivey A; Hills RK; Mills KI; Gale RE; Kaiser MF; Dillon R; Joannides M; Gilkes A; Haferlach T; Schnittger S; Duprez E; Linch DC; Delwel R; Löwenberg B; Baldus CD; Solomon E; Burnett AK; Grimwade D
Blood; 2015 May; 125(19):2985-94. PubMed ID: 25805812
[TBL] [Abstract][Full Text] [Related]
29. High serum extracellular vesicle miR-10b expression predicts poor prognosis in patients with acute myeloid leukemia.
Fang Z; Wang X; Wu J; Xiao R; Liu J
Cancer Biomark; 2020; 27(1):1-9. PubMed ID: 31594209
[TBL] [Abstract][Full Text] [Related]
30. RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures.
Mendler JH; Maharry K; Radmacher MD; Mrózek K; Becker H; Metzeler KH; Schwind S; Whitman SP; Khalife J; Kohlschmidt J; Nicolet D; Powell BL; Carter TH; Wetzler M; Moore JO; Kolitz JE; Baer MR; Carroll AJ; Larson RA; Caligiuri MA; Marcucci G; Bloomfield CD
J Clin Oncol; 2012 Sep; 30(25):3109-18. PubMed ID: 22753902
[TBL] [Abstract][Full Text] [Related]
31. Methylation-independent ITGA2 overexpression is associated with poor prognosis in de novo acute myeloid leukemia.
Lian XY; Zhang W; Wu DH; Ma JC; Zhou JD; Zhang ZH; Wen XM; Xu ZJ; Lin J; Qian J
J Cell Physiol; 2018 Dec; 233(12):9584-9593. PubMed ID: 30132837
[TBL] [Abstract][Full Text] [Related]
32. High expression levels of the ETS-related gene, ERG, predict adverse outcome and improve molecular risk-based classification of cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B Study.
Marcucci G; Maharry K; Whitman SP; Vukosavljevic T; Paschka P; Langer C; Mrózek K; Baldus CD; Carroll AJ; Powell BL; Kolitz JE; Larson RA; Bloomfield CD;
J Clin Oncol; 2007 Aug; 25(22):3337-43. PubMed ID: 17577018
[TBL] [Abstract][Full Text] [Related]
33. NRAS
Pan L; Liang F; Chen X; Hao Z; Muyey DM; Chen X; Wang H
Ann Clin Lab Sci; 2023 May; 53(3):389-397. PubMed ID: 37437942
[TBL] [Abstract][Full Text] [Related]
34. Overexpression of CTNNB1: Clinical implication in Chinese de novo acute myeloid leukemia.
Li XX; Guo H; Zhou JD; Wu DH; Ma JC; Wen XM; Zhang W; Xu ZJ; Lin J; Jun Q
Pathol Res Pract; 2018 Mar; 214(3):361-367. PubMed ID: 29496308
[TBL] [Abstract][Full Text] [Related]
35. Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia.
Ribeiro AF; Pratcorona M; Erpelinck-Verschueren C; Rockova V; Sanders M; Abbas S; Figueroa ME; Zeilemaker A; Melnick A; Löwenberg B; Valk PJ; Delwel R
Blood; 2012 Jun; 119(24):5824-31. PubMed ID: 22490330
[TBL] [Abstract][Full Text] [Related]
36. Mitogen-activated protein kinase binding protein 1 (MAPKBP1) is an unfavorable prognostic biomarker in cytogenetically normal acute myeloid leukemia.
Fu L; Shi J; Hu K; Wang J; Wang W; Ke X
Oncotarget; 2015 Apr; 6(10):8144-54. PubMed ID: 25924238
[TBL] [Abstract][Full Text] [Related]
37. Methylation-independent CHFR expression is a potential biomarker affecting prognosis in acute myeloid leukemia.
Zhou JD; Zhang TJ; Li XX; Ma JC; Guo H; Wen XM; Yao DM; Zhang W; Lin J; Qian J
J Cell Physiol; 2018 Jun; 233(6):4707-4714. PubMed ID: 29115660
[TBL] [Abstract][Full Text] [Related]
38. High meningioma 1 (MN1) expression as a predictor for poor outcome in acute myeloid leukemia with normal cytogenetics.
Heuser M; Beutel G; Krauter J; Döhner K; von Neuhoff N; Schlegelberger B; Ganser A
Blood; 2006 Dec; 108(12):3898-905. PubMed ID: 16912223
[TBL] [Abstract][Full Text] [Related]
39. The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations.
Zheng WS; Hu YL; Guan LX; Peng B; Wang SY
Hematology; 2021 Dec; 26(1):179-185. PubMed ID: 33594943
[TBL] [Abstract][Full Text] [Related]
40. A stem cell-like gene expression signature associates with inferior outcomes and a distinct microRNA expression profile in adults with primary cytogenetically normal acute myeloid leukemia.
Metzeler KH; Maharry K; Kohlschmidt J; Volinia S; Mrózek K; Becker H; Nicolet D; Whitman SP; Mendler JH; Schwind S; Eisfeld AK; Wu YZ; Powell BL; Carter TH; Wetzler M; Kolitz JE; Baer MR; Carroll AJ; Stone RM; Caligiuri MA; Marcucci G; Bloomfield CD
Leukemia; 2013 Oct; 27(10):2023-31. PubMed ID: 23765227
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
